Should You Buy STAAR Surgical Company Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, STAAR Surgical Company (STAA) carries a solid Quality of Company rating of 6.8/10. Trading at $22.45, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 1 of 3 CirclFi valuation models project upside for STAAR Surgical Company (STAA) at $22.45 — the model consensus leans bearish, with a Quality Score of 6.8/10 and Value-Trap risk of 24/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for STAAR Surgical Company (STAA) in 2026?
What Is the Bull Case vs the Bear Case for STAAR Surgical Company (STAA)?
| Bull case — $34.16 target (+52.2%) | Bear case — $2.52 target (-88.8%) |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $34.16 (+52.2%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, the Earnings Power Value (EPV) model sees the stock as overvalued with a fair value of $2.52 (-88.8%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +141.0% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
How Does STAA Compare to Its Medical Instruments & Supplies Peers?
Valuation data pages: BLFS · OSUR · NXGL · ANGO · SMTI · AVTR · STXS · ALC · PDEX · ISRG · RMD
Which Other Stocks Score Like STAA on Quality?
Closest companies to STAA’s Quality of Company score of 6.8/10, across all industries.
- OI — O-I Glass, Inc. (QOC 6.8) · analysis
- ICCC — ImmuCell Corporation (QOC 6.8) · analysis
- CIZN — Citizens Holding Company (QOC 6.8) · analysis
- BHIC — BioScience Health Innovations I (QOC 6.8) · analysis
- VSH — Vishay Intertechnology, Inc. (QOC 6.8) · analysis
- REAX — Real REMAX Group Inc. (QOC 6.8) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Instruments & Supplies Screens Does STAA Appear In?
So Is STAAR Surgical Company (STAA) Worth Buying in 2026?
Caution dominates our read on STAAR Surgical Company at $22.45. 2 of 3 models see limited upside or outright downside, with the median fair value at $20.41 (-9.1%). Quality at 6.8/10 provides some fundamental cushion. Current holders should re-evaluate their thesis; new buyers should demand a wider margin of safety.
These are quantitative model outputs, not investment recommendations. STAAR Surgical Company's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About STAA Stock?
Should I buy STAA stock right now?
Based on CirclFi's multi-model analysis, 1 of 3 models see upside for STAA at $22.45. The models are divided, which means the investment case depends heavily on your assumptions about STAAR Surgical Company's future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in STAAR Surgical Company?
Key risks include: limited model coverage (3/13 active), reducing analytical confidence; wide model disagreement (1257% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Instruments & Supplies companies. Always diversify and consult a financial advisor.
How does STAA compare to its competitors?
Among Medical Instruments & Supplies peers, STAA holds a Quality Score of 6.8/10. Comparable companies include BLFS (QOC 6.9), OSUR (QOC 6.8), NXGL (QOC 7.0). The relative ranking helps investors identify whether STAA offers better fundamental quality than alternatives in the same sector.
Is STAA a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. STAA's Quality Score of 6.8/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy STAA at?
CirclFi does not provide target buy prices or price alerts. However, our 3 active models produce fair value estimates ranging from $2.52 to $34.16. At $22.45, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for STAA.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad